



Final Appraisal Recommendation

Advice No: 1812 – July 2012

Darunavir (Prezista®) 800 mg once daily film-coated tablets

Submission by Janssen-Cilag Ltd

Recommendation of the All Wales Medicines Strategy Group

Darunavir (Prezista®) 800 mg once daily, co-administered with low dose ritonavir, is recommended as an option for use within NHS Wales for the treatment of HIV-1 infection in antiretroviral therapy-experienced adults with no darunavir resistance-associated mutations and who have plasma HIV-1 RNA <100,000 copies/mL and CD4+ cell count $\geq 100 \text{ cells} \times 10^6/\text{l}$.

Additional note:

- AWMSG is of the opinion that darunavir (Prezista®) is appropriate for specialist only prescribing within NHS Wales for the stated indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1336), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1812: Darunavir (Prezista®) 800 mg once daily film-coated tablets. July 2012.